Stock RNAZ TRANSCODE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
0.707 USD +12.26% Intraday chart for TransCode Therapeutics, Inc. +34.67% -89.27%
04-22 Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
04-22 Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI

Evolution of the average Target Price on TransCode Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ed5584b74d.SbLNta_0KETQegmNBjnBmP95boW1mHXoIkD9qvP72wk.f9_5z83CcDO1MD-6Qm-X6otMBtXfwiCLaHmu6LfOsn8xhK7mnKdEF708ag~f927e3d9af87467934aafe046b6b4081

Analyst Recommendations on TransCode Therapeutics, Inc.

Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision MT
Traders Stay Cautious Ahead of Fed Rate Decision, Weighing on US Equity Futures MT
HC Wainwright Adjusts Price Target on TransCode Therapeutics to $6 From $10, Maintains Buy Rating MT
HC Wainwright Starts TransCode Therapeutics at Buy With $10 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.707 USD
Average target price
3 USD
Spread / Average Target
+324.33%
High Price Target
3 USD
Spread / Highest target
+324.33%
Low Price Target
3 USD
Spread / Lowest Target
+324.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering TransCode Therapeutics, Inc.

HC Wainwright

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. Consensus TransCode Therapeutics, Inc.